ARGX argenx SE Quick Ratio

A steady stream of profit ensures an unrivaled demand for the drug Vyvgart. The production cycle relies on a hybrid network of contract manufacturing sites in the US and Europe. Exclusive patents allow argenx SE (ARGX) to independently determine the high cost of therapy. The quick ratio demonstrates current solvency, where a metric value of 4.93 confirms the ability to settle short-term debts without relying on inventory.

argenx SE specializes in high-cost targeted therapy for rare autoimmune pathologies, receiving payments from Western healthcare systems. The rapid liquidity trajectory reflects the company's ability to settle obligations using cash and accounts receivable, excluding illiquid inventories. The current value of 4.93 demonstrates the real solvency margin without accounting for warehouse stocks. This indicator allows investors to assess the asset's financial stability and the efficiency of working capital management.